联环药业：关于控股子公司获得《药品注册证书》的公告

Group 1 - The core announcement is that Lianhuan Pharmaceutical's subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has received the drug registration certificate from the National Medical Products Administration for the drug named Meiasartan Potassium Tablets [2] Group 2 - The approval of the drug registration certificate indicates a significant regulatory milestone for the company, potentially enhancing its product portfolio and market presence [2] - The drug Meiasartan Potassium Tablets may contribute to the company's revenue growth and competitive positioning in the pharmaceutical industry [2]